Cargando…

Profile of panobinostat and its potential for treatment in solid tumors: an update

The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both intravenous and oral formulations across multiple tumor types. Comparable to the other HDACs, panobino...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anne, Madhurima, Sammartino, Daniel, Barginear, Myra F, Budman, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833618/ https://www.ncbi.nlm.nih.gov/pubmed/24265556 http://dx.doi.org/10.2147/OTT.S30773

Ejemplares similares

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors
por: Savelieva, Marina, et al.
Publicado: (2015)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

Profile of farletuzumab and its potential in the treatment of solid tumors
por: Sato, Seiya, et al.
Publicado: (2016)

Panobinostat for the treatment of multiple myeloma: the evidence to date
por: Bailey, Hanna, et al.
Publicado: (2015)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
por: Runcie, Karie, et al.
Publicado: (2018)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
por: Bauer, S, et al.
Publicado: (2014)

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013)

Antifungal Activity and Potential Mechanism of Panobinostat in Combination With Fluconazole Against Candida albicans
por: Su, Shan, et al.
Publicado: (2020)

Renal Medullary Carcinoma Masquerading as Bilateral Breast Carcinoma Category: Case Report
por: Anne, Madhurima, et al.
Publicado: (2013)

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression()
por: Groselj, Blaz, et al.
Publicado: (2013)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
por: Zopf, Steffen, et al.
Publicado: (2012)

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
por: Afolabi, Lukman O., et al.
Publicado: (2021)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

EMBR-28. CNS DISTRIBUTIONAL KINETICS OF PANOBINOSTAT IN THE MOUSE
por: Zhang, Wenqiu, et al.
Publicado: (2021)

Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells
por: Choi, Changhoon, et al.
Publicado: (2021)

Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma
por: Wirries, André, et al.
Publicado: (2018)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2022)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Zap‐Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat
por: Troelsen, Kathrin S., et al.
Publicado: (2021)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2017)

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
por: Singh, Avineesh, et al.
Publicado: (2016)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
por: Harttrampf, Anne Catherine, et al.
Publicado: (2021)

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC
por: Cai, Yang, et al.
Publicado: (2015)

A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
por: Samaraweera, Leleesha, et al.
Publicado: (2017)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Design and synthesis of diazine-based panobinostat analogues for HDAC8 inhibition
por: Balasubramaniam, Sivaraman, et al.
Publicado: (2020)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines
por: Pacheco, Mariana Brütt, et al.
Publicado: (2021)

Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
por: Chong, Wai C., et al.
Publicado: (2021)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
por: Di Fazio, Pietro, et al.
Publicado: (2010)

Evaluation of the cytotoxic and immunogenic potential of temozolamide, panobinostat, and Lophophora williamsii extract against C6 glioma cells
por: Franco-Molina, Moisés Armides, et al.
Publicado: (2021)

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
por: Xia, Chang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lqauuhrpq4hapm7074hn7nft1m